Neoadjuvant Nivolumab + Ipilimumab Could Be New SOC in Stage III Melanoma

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the NADINA trial, which compared neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma. This abstract will be presented as LBA2 during the Plenary Session at the 2024 ASCO Annual Meeting.
Read the full abstract: meetings.asco....
For more on ASCO24, visit dailynews.asco...